Rättö Hanna
The Social Insurance Institution, Kela Research, Helsinki, PO Box 450, 00056, Kela, Finland.
SSM Popul Health. 2022 Aug 9;19:101178. doi: 10.1016/j.ssmph.2022.101178. eCollection 2022 Sep.
Inequalities in access to care can translate to or strengthen existing inequalities in health if people of lower socioeconomic positions do not have equal access to care. I study insulin initiation among individuals with type 2 diabetes and examine whether a reform increasing the co-payment of non-insulin antidiabetics in Finland in 2017 had an inequitable effect on the initiation. In the treatment of type 2 diabetes, insulin is recommended only in later stages and remains covered by the National Health Insurance at a rate of 100%.
I evaluated the effect of the reform with Cox proportional hazard modelling using nationwide person-level register data from 2011 to 2019. Exploiting a quasi-experimental design rising from the introduction of the reform allows for consideration of causality.
I found that the risk of insulin initiation was lower in the later years of the study period. Additionally, individuals in lower socioeconomic positions had a higher risk of initiation. However, I did not find inequalities in how the reform affected the risk of insulin initiation between income quintiles.
Co-payments are unlikely to be the most influential factor behind persisting inequalities in insulin initiation among individuals with type 2 diabetes in Finland. Lower risk in the later years aligns with developing treatment practices of type 2 diabetes.
如果社会经济地位较低的人群无法平等获得医疗服务,那么在医疗服务可及性方面的不平等可能会转化为或加剧现有的健康不平等。我研究了2型糖尿病患者开始使用胰岛素的情况,并考察了2017年芬兰一项提高非胰岛素类抗糖尿病药物自付费用的改革是否对胰岛素起始治疗产生了不公平影响。在2型糖尿病的治疗中,胰岛素仅在后期阶段被推荐使用,并且仍由国家健康保险100%承保。
我使用2011年至2019年全国个人层面的登记数据,通过Cox比例风险模型评估了这项改革的效果。利用改革引入所产生的准实验设计可以考虑因果关系。
我发现,在研究期间的后期,开始使用胰岛素的风险较低。此外,社会经济地位较低的个体起始治疗的风险较高。然而,我没有发现在改革如何影响不同收入五分位数人群胰岛素起始治疗风险方面存在不平等。
自付费用不太可能是芬兰2型糖尿病患者在胰岛素起始治疗方面持续存在不平等的最具影响力的因素。后期风险较低与2型糖尿病治疗实践的发展相一致。